The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PLSE | -18.93% | -29.71% | -6.8% | +250% |
| S&P | +14.77% | +87.2% | +13.35% | +239% |
Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $86.00K | 0.0% |
| Gross Profit | -$449.00K | -68.2% |
| Gross Margin | -522.09% | 0.0% |
| Market Cap | $1.19B | 10.8% |
| Market Cap / Employee | $15.88M | 0.0% |
| Employees | 75 | 33.9% |
| Net Income | -$19,385.00K | -52.9% |
| EBITDA | -$20,111.00K | -50.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $95.21M | 20.5% |
| Accounts Receivable | $15.00K | 0.0% |
| Inventory | 0.1 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $6.37M | -11.2% |
| Short Term Debt | $1.52M | 27.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -74.06% | -16.0% |
| Return On Invested Capital | -98.55% | 16.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$13,101.00K | -44.6% |
| Operating Free Cash Flow | -$13,039.00K | -44.5% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 13.53 | 9.23 | 8.57 | 11.40 | -68.27% |
| Price to Sales | 13868.77 | - | |||
| Price to Tangible Book Value | 14.29 | 9.57 | 8.86 | 11.81 | -72.40% |
| Enterprise Value to EBITDA | -53.73 | -54.58 | -45.84 | -54.96 | -26.45% |
| Return on Equity | -67.3% | -77.9% | -103.5% | -87.0% | 23.77% |
| Total Debt | $8.90M | $8.58M | $8.25M | $7.89M | -5.70% |
No podcast episodes available.
PLSE earnings call for the period ending September 30, 2020.
PLSE earnings call for the period ending June 30, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
